Nursing care
Anticoagulation in Pregnancy, explained for the bedside and the exam
Written and reviewed by Dana Whitfield, RN, MSN · 6 min read · Updated September 2026
Short answer
Heparin is the anticoagulant of choice in pregnancy because it does not cross the placenta, while warfarin does and carries teratogenic risk. Low molecular weight heparin is preferred over unfractionated heparin for most indications, with monitoring and dosing adjusted through each trimester and around delivery.
What the concept actually says
Anticoagulation in pregnancy is not a dosing question. It is a drug-selection question, and the placenta decides the answer. Heparin, whether unfractionated or low molecular weight, is a large charged molecule that does not cross the placental barrier. Warfarin does cross, and it is teratogenic in the first trimester and associated with fetal bleeding and CNS abnormalities later in pregnancy. That single fact removes warfarin from the standard regimen for the entire pregnancy, not just the first trimester.
Low molecular weight heparin, typically enoxaparin, is now the first-line agent for most pregnant patients needing anticoagulation, whether for a mechanical valve, a history of venous thromboembolism, or antiphospholipid syndrome. Unfractionated heparin still has a role, particularly close to delivery, because its effect can be reversed quickly with protamine sulfate and it has a shorter half-life. Direct oral anticoagulants are avoided outright; data in pregnancy is limited and the safety profile is not established.
The clinical reasoning behind it
The reasoning starts with molecular size and charge. Heparin is a large, highly sulfated polysaccharide that cannot cross the placenta in meaningful amounts, so it does not directly affect the fetus. Warfarin is small and lipophilic, crosses freely, and interferes with the fetal synthesis of vitamin K-dependent clotting factors during a period when the fetal skeleton and central nervous system are actively forming. That is the mechanism behind warfarin embryopathy: nasal hypoplasia, stippled epiphyses, and later intracranial hemorrhage.
This is why a patient who is stable on warfarin before conception is switched to heparin as soon as pregnancy is confirmed, ideally before six weeks gestation. The exception nurses need to know is the mechanical heart valve population, where some cardiologists continue warfarin through parts of pregnancy because heparin carries a higher risk of valve thrombosis in that specific group. That exception does not change the general rule; it explains why the rule is applied by a multidisciplinary team weighing maternal and fetal risk together.
Applying it under time pressure
At the bedside, the fast checks are: confirm the agent is heparin-based, confirm the indication, and confirm the patient has not been handed a warfarin prescription by mistake during a care transition. If a pregnant patient on anticoagulation reports gum bleeding, unusual bruising, or heavy vaginal bleeding, hold the next dose and notify the provider before assuming it is unrelated.
With low molecular weight heparin, routine aPTT monitoring is not required; anti-Xa levels are used instead when monitoring is indicated, usually four to six hours after a dose. With unfractionated heparin, aPTT is checked per protocol, generally every six hours until therapeutic, then daily. Platelet counts are checked periodically to screen for heparin-induced thrombocytopenia, particularly in the first two weeks of unfractionated heparin therapy. Around 36 weeks or as delivery approaches, many patients are transitioned from low molecular weight heparin to unfractionated heparin or have therapy held, specifically because unfractionated heparin's effect is reversible and its half-life is shorter, which matters if neuraxial anesthesia or an urgent delivery is needed.
Common misconceptions
The most persistent misconception is that warfarin is simply riskier and heparin is simply safer, as a general statement. The precise fact is narrower: warfarin crosses the placenta and heparin does not, and that crossing is what drives the teratogenic and hemorrhagic risk to the fetus. A nurse who states the reasoning as placental crossing, not vague risk, will reason correctly through edge cases like the mechanical valve exception.
A second misconception is that all heparin products are interchangeable at the bedside. Low molecular weight heparin and unfractionated heparin differ in monitoring, reversal, and timing around delivery, and mixing up the two on an exam question or in a medication reconciliation is a common error. A third misconception is that anticoagulation is stopped outright once pregnancy is confirmed; it is switched to a placenta-safe agent, not discontinued, because the underlying thrombotic risk has not gone away.
Practice scenarios
A patient with a history of deep vein thrombosis, currently on warfarin, tells you she suspects she is pregnant. The priority action is to hold warfarin and notify the provider for an immediate switch to low molecular weight heparin, because every day on warfarin in early pregnancy carries teratogenic risk during organogenesis.
A patient at 37 weeks on enoxaparin is scheduled for induction in two days. The expected order is a transition to unfractionated heparin or a planned hold, so the effect can be reversed or has worn off in time for neuraxial anesthesia, reducing the risk of epidural hematoma. A third scenario: a patient on unfractionated heparin develops a falling platelet count on day nine of therapy. This should raise concern for heparin-induced thrombocytopenia, and the nurse should notify the provider rather than assume it is incidental.
Key takeaways
Heparin does not cross the placenta; warfarin does. That single fact is why heparin, usually low molecular weight, is the anticoagulant of choice throughout pregnancy for most indications. Direct oral anticoagulants are avoided due to insufficient safety data.
Monitoring differs by agent: anti-Xa for low molecular weight heparin when needed, aPTT for unfractionated heparin, and periodic platelet counts to screen for heparin-induced thrombocytopenia. Near delivery, many patients are transitioned to unfractionated heparin or held, because its effect is reversible and short-lived, which matters for neuraxial anesthesia and delivery timing.
The next step on this is the same as on everything else here: answer questions and read the rationales. Our pharmacology practice questions are the closest set to what this page covers.
One question from the pharmacology set
A client with heart failure is started on furosemide 40 mg PO daily. Which findings should the nurse report to the provider before administering the next dose? Select all that apply.
Rationale
Furosemide is a loop diuretic, so the two things you are watching are potassium and kidney function. A potassium of 2.9 mEq/L is below the 3.5–5.0 reference range and puts the client at risk for dysrhythmia — hold and report. Muscle cramps with palpitations are the clinical face of that same hypokalemia, so they are reported together, not separately. A creatinine that doubles signals the diuresis has outrun renal perfusion. A blood pressure of 132/78 and a 1 kg loss are the expected response to the drug working, not reasons to hold it.
Answer: A, D, E
Common questions
Why can't pregnant patients take warfarin?
Warfarin crosses the placenta and can cause fetal malformations, particularly nasal hypoplasia and skeletal abnormalities, when exposure occurs during the first trimester. Later in pregnancy it carries a risk of fetal intracranial hemorrhage. Heparin does not cross the placenta and is used instead for essentially the whole pregnancy.
Is low molecular weight heparin or unfractionated heparin preferred in pregnancy?
Low molecular weight heparin, such as enoxaparin, is preferred for most indications because it has a more predictable dose response and does not usually require routine lab monitoring. Unfractionated heparin is favored closer to delivery because its effect can be reversed quickly with protamine sulfate and its half-life is shorter.
What should a nurse monitor in a pregnant patient on anticoagulation?
Watch for signs of bleeding, such as gum bleeding, easy bruising, or heavy vaginal bleeding, and monitor platelet counts to screen for heparin-induced thrombocytopenia, especially in the first two weeks of unfractionated heparin therapy. Anti-Xa levels are checked for low molecular weight heparin when monitoring is indicated, and aPTT is checked per protocol for unfractionated heparin.
Are direct oral anticoagulants used in pregnancy?
No. Direct oral anticoagulants such as rivaroxaban and apixaban are avoided in pregnancy because there is not enough safety data to establish they do not harm the fetus. Heparin remains the standard of care.
Why would a pregnant patient with a mechanical heart valve stay on warfarin?
Some cardiologists continue warfarin in patients with mechanical heart valves because heparin carries a higher risk of valve thrombosis in this specific population. This decision is made by a multidisciplinary team weighing the maternal risk of valve failure against fetal risk, and it does not change the general rule for other indications.
More on pharmacology
Guides on this